(SLXP) Salix Pharmaceuticals – Bull of the Day

Salix Pharmaceuticals (SLXP) third quarter results exceeded expectations with higher revenues boosting performance. With the company raising its revenue guidance, we have raised our estimates as well. Salix is well-positioned for growth in the gastrointestinal market.

We believe lead product Xifaxan will continue to experience solid, above-market trend growth given its safety profile and lack of systemic absorption. We were pleased to see Xifaxan gain approval for the hepatic encephalopathy indication, as we believe that the main potential for Salix lies in gaining approval for additional indications for Xifaxan.

Meanwhile, we are pleased to see the company expanding its pipeline through in-licensing deals and acquisitions. We expect the company to continue pursuing suitable in-licensing opportunities in order to grow revenues. We believe the current price represents an attractive entry point for long-term investors and maintain our Outperform recommendation on the stock.

SALIX PHARM-LTD (SLXP): Free Stock Analysis Report

Zacks Investment Research

About vitalstocks

This is a sample profile field. Vitalstocks is the operating company for Stockbloghub. This will place the picture of the author or company in the profile. Here is another extra line of information.


Powered by Facebook Comments

Similar Posts: | | Drug Related Products | Healthcare

RSS feeds: Salix Pharmaceuticals Limited | SLXP | Drug Related Products | Healthcare |

Other Posts by | RSS Feed for this author